Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance. 

In a study investigating active surveillance, pathologic progression was the main reason that men progressed to treatment, states Feldman. On a future biopsy, these men had an increased volume of disease or an increase of Gleason score.  

Other reasons men progressed to treatment included a higher prostate-specific antigen (PSA) density, which correlates with higher volume of disease, explains Feldman. 

Videos

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

In this study, 432 men with a median age of 55 were put on active surveillance. Historically, men under 60 have not been recommended for active surveillance due to risk of aggressive disease or progression.

At 5 years, 75% of men remained on active surveillance, and at 10 years, 55% of men remained on active surveillance.

Dr. Feldman on Study of Active Surveillance in Younger Men With Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Even biopsies that do not show cancer, but are near cancer, have similar metabolomic changes to the specimens nearby that show cancer, says Feldman.

Feldman hopes that these metabolomic findings can be translated into regular prostate MRIs.

Dr. Feldman Discusses Metabolomic Findings in Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.
 

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer. 

An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman. 

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Although, most men respond well to treatments for prostate cancer, there are significant adverse events to consider, explains Feldman.

Active surveillance is beneficial to a man whose prostate cancer may never affect him and help him to avoid potential side effects from treatment, states Feldman.

Dr. Feldman on the Significance of Active Surveillance in Prostate Cancer

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.

For men with low- to intermediate-risk prostate cancer, active surveillance is an option for attempting to avoid treatment. There is a study that focused on active surveillance in men under 60 years old. Historically, active surveillance has been avoided in younger men for the concern that they will eventually need treatment or harbor a more aggressive disease.

In this study, there were 432 men with a median age of 55 years. The median time of follow-up was 5.1 years.

Adam Scott Feldman, MD, MPH

Articles